INT12292

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1980
Last Reported 2010
Negated 2
Speculated 0
Reported most in Abstract
Documents 22
Total Number 22
Disease Relevance 5.02
Pain Relevance 8.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (GH1) extracellular region (GH1)
Anatomy Link Frequency
plasma 2
pituitary 2
GH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 51 100.00 Very High Very High Very High
dexamethasone 16 100.00 Very High Very High Very High
narcan 19 99.98 Very High Very High Very High
Sumatriptan 6 99.98 Very High Very High Very High
Dopamine 45 99.84 Very High Very High Very High
antagonist 7 99.74 Very High Very High Very High
Arthritis 10 99.62 Very High Very High Very High
Inflammation 22 99.20 Very High Very High Very High
Enkephalin 6 98.62 Very High Very High Very High
Somatostatin 44 98.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Thyroid Disease 8 100.00 Very High Very High Very High
Adrenal Cancer 91 99.98 Very High Very High Very High
Hypercalcemia 4 99.70 Very High Very High Very High
Arthritis 11 99.62 Very High Very High Very High
INFLAMMATION 19 99.20 Very High Very High Very High
Stress 1 98.58 Very High Very High Very High
Diabetes Mellitus 12 98.40 Very High Very High Very High
Brain Injury 2 96.84 Very High Very High Very High
Pancreatitis 1 94.88 High High
Iron Overload 1 93.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have administered the long-acting met-enkephalin analogue DAMME to 6 normal males, and have shown that the resulting elevation in GH is blocked by the specific cholinergic antagonist, pirenzepine.
Negative_regulation (blocked) of Positive_regulation (elevation) of GH associated with antagonist and enkephalin
1) Confidence 0.58 Published 1983 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 6409456 Disease Relevance 0 Pain Relevance 0.40
Elevated GH levels following clonidine administration abolished GH responses to subsequently infused 2DG (P less than 0.05).
Negative_regulation (abolished) of Positive_regulation (Elevated) of GH associated with clonidine
2) Confidence 0.57 Published 1985 Journal Metab. Clin. Exp. Section Abstract Doc Link 3982277 Disease Relevance 0.07 Pain Relevance 0.61
Naloxone pretreatment resulted in a significantly reduced GH increase after the clonidine infusion.
Negative_regulation (reduced) of Positive_regulation (increase) of GH associated with narcan and clonidine
3) Confidence 0.45 Published 1984 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6319449 Disease Relevance 0.16 Pain Relevance 1.08
After pre-treatment with cyproheptadine, an anti-serotoninergic drug known to inhibit GH secretion, the mean integrated sumatriptan-induced GH response decreased from 14.8 +/- 3.9 muI/l*hr to 3.7 +/- 1.7 mIU/l*hr.
Negative_regulation (decreased) of Positive_regulation (induced) of GH associated with sumatriptan
4) Confidence 0.43 Published 1994 Journal Neuropharmacology Section Abstract Doc Link 8035909 Disease Relevance 0.08 Pain Relevance 0.52
Individually considered, practically all control children, but only 2 of 12 GH-deficient children, presented a dexamethasone-induced GH peak over the 10 micrograms/L level.
Negative_regulation (presented) of Positive_regulation (dexamethasone-induced) of GH associated with dexamethasone
5) Confidence 0.41 Published 1992 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 1639956 Disease Relevance 0.14 Pain Relevance 0.32
Pirenzepine, a cholinergic muscarinic antagonist, completely blocked the GH rise induced by dopamine- and adreno-receptor stimulation.
Negative_regulation (blocked) of Positive_regulation (induced) of GH associated with dopamine and antagonist
6) Confidence 0.40 Published 1983 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6688812 Disease Relevance 0 Pain Relevance 0.31
Patients with hyperthyroidism have reduced growth hormone (GH) responses to pharmacological stimuli and reduced spontaneous nocturnal GH secretion.
Negative_regulation (reduced) of Positive_regulation (responses) of GH associated with thyroid disease
7) Confidence 0.39 Published 1991 Journal Horm. Res. Section Abstract Doc Link 1823078 Disease Relevance 0.51 Pain Relevance 0.24
Our data demonstrate that the GH responses to clonidine as well as to GHRH in patients with hyperthyroidism are inhibited in a similar fashion with respect to normal subjects.
Negative_regulation (inhibited) of Positive_regulation (responses) of GH associated with thyroid disease and clonidine
8) Confidence 0.39 Published 1991 Journal Horm. Res. Section Abstract Doc Link 1823078 Disease Relevance 0.49 Pain Relevance 0.62
The simultaneous infusion of naloxone blocked melatonin-induced GH rise.
Negative_regulation (blocked) of Positive_regulation (melatonin-induced) of GH associated with narcan
9) Confidence 0.39 Published 1988 Journal J. Endocrinol. Invest. Section Abstract Doc Link 3361078 Disease Relevance 0 Pain Relevance 0.71
Compared to controls, depressed patients showed a significant attenuation of net growth hormone (GH) responses to GHRH associated with normal basal GH concentrations.
Negative_regulation (attenuation) of Positive_regulation (responses) of GH
10) Confidence 0.37 Published 1988 Journal Psychiatry Res Section Abstract Doc Link 3141943 Disease Relevance 0.23 Pain Relevance 0.29
Naloxone alone had no hormonal effect but abolished the increase in PRL and GH following injection of FK 33-824 without modifying the decrease in plasma cortisol or the increase in free water clearance following the same treatment.
Negative_regulation (abolished) of Positive_regulation (increase) of GH in plasma associated with narcan
11) Confidence 0.33 Published 1980 Journal Horm. Res. Section Abstract Doc Link 6262206 Disease Relevance 0 Pain Relevance 0.28
Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
Negative_regulation (blockade) of Positive_regulation (response) of GH
12) Confidence 0.29 Published 1991 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 1677361 Disease Relevance 0 Pain Relevance 0.28
Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
Negative_regulation (blockade) of Positive_regulation (response) of GH
13) Confidence 0.29 Published 1991 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 1677361 Disease Relevance 0 Pain Relevance 0.28
GH response to clonidine as well as integrated and mean nocturnal GH secretion were significantly depressed after LTPT v. before treatment.
Negative_regulation (depressed) of Positive_regulation (response) of GH associated with clonidine
14) Confidence 0.29 Published 1995 Journal J. Trop. Pediatr. Section Abstract Doc Link 8606442 Disease Relevance 0 Pain Relevance 0.59
Exogenous growth hormone (hGH) administration in humans attenuates the endogenous growth hormone (GH) response to some pharmacological stimuli; in particular, pretreatment with hGH completely blocks the serum GH response to growth hormone-releasing hormone.
Negative_regulation (attenuates) of Positive_regulation (response) of GH
15) Confidence 0.25 Published 1996 Journal Eur. J. Endocrinol. Section Abstract Doc Link 8590960 Disease Relevance 0 Pain Relevance 0.15
Mild hypercalcaemia significantly diminished the GH response to arginine in patients with secondary diabetes, but not in those with ID.
Neg (not) Negative_regulation (diminished) of Positive_regulation (response) of GH associated with diabetes mellitus and hypercalcemia
16) Confidence 0.24 Published 1984 Journal Horm. Metab. Res. Section Abstract Doc Link 6532933 Disease Relevance 1.06 Pain Relevance 0.09
On the contrary, longer Dex treatments suppress GHRH-induced GH values (6.0 +/- 1.1 ng/ml after Dex 8 mg and 1.8 +/- 0.3 ng/ml after Dex 22 mg).
Negative_regulation (suppress) of Positive_regulation (values) of GH associated with dexamethasone
17) Confidence 0.21 Published 1990 Journal Neuroendocrinology Section Abstract Doc Link 2106087 Disease Relevance 0.15 Pain Relevance 0.65
Three months after the head injury, the hormonal evaluation of the hypothalamic-pituitary axis by means of insulin stress test with the simultaneous administration of TRH and GnRH resulted in reduced responses of GH, cortisol, TSH, FSH, and LH with low baseline serum concentrations of free T4 and testosterone.
Negative_regulation (reduced) of Positive_regulation (responses) of GH in pituitary associated with stress and brain injury
18) Confidence 0.20 Published 1996 Journal J. Endocrinol. Invest. Section Abstract Doc Link 8796342 Disease Relevance 0.81 Pain Relevance 0.10
Indeed, there appears to be excellent evidence that growth restriction with chronic inflammation, including arthritis, is the result of suppression of IGF-1 production and activity, independent of GH, and in response to IL-6 [41,42].
Negative_regulation (suppression) of Neg (independent) Positive_regulation (independent) of GH associated with inflammation and arthritis
19) Confidence 0.13 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1456997 Disease Relevance 0.57 Pain Relevance 0.24
Thirdly, antagonism of peripheral GH receptors blocks the action of GH at the receptor which inhibits the synthesis of IGF-1 and lowers serum levels; GH levels remain elevated [94], but are blocked by the medication.
Negative_regulation (blocked) of Positive_regulation (elevated) of GH
20) Confidence 0.08 Published 2010 Journal BMC Endocr Disord Section Body Doc Link PMC2887860 Disease Relevance 0.36 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox